2026³â08¿ù30ÀÏsun
·Î±×ÀÎ | ȸ¿ø°¡ÀÔ
OFF
Æ®À§ÅÍ·Î º¸³»±â ½ÎÀÌ¿ùµå °ø°¨
±â»ç±ÛÈ®´ë ±â»ç±ÛÃà¼Ò ±â»ç½ºÅ©·¦ À̸ÞÀϹ®ÀÇ ÇÁ¸°Æ®Çϱâ
Ç÷¾×ÇÐȸ Ãß°èÇмú´ëȸ 150¿©¸í Âü¿© '¼º·á'
[ 2004³â 11¿ù 07ÀÏ 08½Ã 12ºÐ ]
Á¦45Â÷ ´ëÇÑÇ÷¾×ÇÐȸ Ãß°èÇмú´ëȸ°¡ ÃÖ±Ù ¿ï»êÇö´ëÈ£ÅÚ¿¡¼­ ±¹³»¿Ü Ç÷¾×ÁúȯºÐ¾ß ¼®ÇÐ 150¿©¸íÀÌ Âü°¡ÇÑ °¡¿îµ¥ ¼ºÈ²¸®¿¡ ³¡³µ´Ù.[»çÁø]

ÇÐȸ´Â "À̹ø Çмú´ëȸ´Â ¹éÇ÷º´ÀÇ ¼¼°èÀûÀÎ ±ÇÀ§ÀÚÀÎ ¹Ì±¹ MD¾Ø´õ½¼ ¾Ï¼¾ÅÍÀÇ Å»ÆÄÁî ¹Ú»ç¸¦ ºñ·ÔÇØ ¿ï»ê´ëº´¿ø ¹ÚÀçÈÄ ±³¼ö µîÀÌ Âü¿©ÇÑ °¡¿îµ¥ ´ë±Ô¸ð·Î Ä¡·ïÁ³´Ù"°í 7ÀÏ ¹àÇû´Ù.

Çмú´ëȸ´Â ¡®High_risk acute leukemia¡¯¿Í ¡®Clinical Issues in coagulation disorders¡¯ÀÇ µÎ °¡Áö Å« ÁÖÁ¦ÀÇ ½ÉÆ÷Áö¾ö°ú ¡®Evolution of therapy for CML (MD Anderson Cancer Center, USA Dr. Moshe Talpaz)¡¯°ú ¡®Current concept of blood coagulation (University of Land, Sweden Dr.Ulla Hedner)¡¯ µî µÎ °³ÀÇ Æ¯°­À¸·Î ÁøÇàµÆ´Ù.

¼¼ºÎ¿¬Á¦·Î´Â ¡âRelapsed and refractory acute leukemia (¿ï»êÀÇ´ë ³»°ú ÀÌÁ¦È¯)¡âHigh-risk childhood acute leukemia (ºÎ»êÀÇ´ë ¼Ò¾Æ°ú ÀÌ¿µÅ¹)¡âUpdate in the pathogenesis and diagnosis of TTP(Æ÷õÁß¹®ÀÇ´ë Áø´ã°Ë»çÀÇÇаú °­¸í¼­)¡âCancer and thrombosis(ÀÎÇÏÀÇ´ë ³»°ú ±èÀÎÈ£) µîÀÌ ¹ßÇ¥µÆ´Ù.

ÇÐȸ °ü°èÀÚ´Â "À̹ø ÇÐȸ°¡ ¹éÇ÷º´À» ºñ·ÔÇÑ Ç÷¾×ÁúȯÀ¸·Î °í»ýÇϰí Àִ ȯÀÚ¿¡ ´ëÇÑ ÀÌÇØ¿Í °ü½ÉÀ» ³ôÀ̰í Ç÷¾×Áúȯ¿¡ ´ëÇÑ °æ°¢½ÉÀ» °íÃë½Ã۴µ¥ Å« µµ¿òÀÌ µÉ °Í"À̶ó°í ¸»Çß´Ù.
¼­À±¾Æ±âÀÚ sya@dailymedi.com
À̱âÀÚÀÇ ´Ù¸¥´º½ºº¸±â
¹«ÅëÀåÀÔ±Ý Á¤º¸ÀÔ·Â ÀÔ±ÝÀÚ¸í ÀԱݿ¹Á¤ÀÏÀÚ
(ÀÔ±ÝÇÏ½Ç ÀÔ±ÝÀÚ¸í + ÀԱݿ¹Á¤ÀÏÀÚ¸¦ ÀÔ·ÂÇϼ¼¿ä)
[°ü·Ã´º½º]
- °ü·Ã´º½º°¡ ¾ø½À´Ï´Ù.
Æ®À§ÅÍ·Î º¸³»±â ½ÎÀÌ¿ùµå °ø°¨
±â»ç±ÛÈ®´ë ±â»ç±ÛÃà¼Ò ±â»ç½ºÅ©·¦ À̸ÞÀϹ®ÀÇ ÇÁ¸°Æ®Çϱâ
¸íÁöº´¿ø, ͺ À̰ÇÈñ ȸÀå ÁÖÄ¡ÀÇ À̰­¿ì ±³¼ö(»ï¼º¼­¿ïº´¿ø ÀçȰÀÇÇаú) ¿µÀÔ
´ëÀü¼º¸ðº´¿ø ±èµ¿±â¡¤À̵¿Ã¢ ±³¼ö, ´ëÇÑÀ̺ñÀÎÈİúÇÐȸ ÃÖ¿ì¼ö ±¸¿¬»ó¡¤ÃÖ¿ì¼ö Æ÷½ºÅÍ»ó
Á¶Àç¿ì ±³¼ö(°í´ë±¸·Îº´¿ø Á¤Çü¿Ü°ú), ´ëÇѰñÀýÇÐȸ ÃÖ´Ù³í¹®»ó
´ëÇÑÀÇ»çÇùȸ ºÎȸÀå ¹éÇö¿í¡¤Àǹ«ÀÌ»ç ¿Àµ¿È£¡¤Á¤º¸Åë½ÅÀÌ»ç À¯¼Ò¿µèâ
Çѱ¹Á¦¾à¹ÙÀÌ¿ÀÇùȸ ÀǾàǰ±¤°í½ÉÀÇÀ§¿øÈ¸ À§¿øÀå ±è¼ºÁø¡¤ºÎÀ§¿øÀå ÀÌÁØÈñ¡¤ÀåÃá°ï èâ
¹è±â¼ö ±³¼ö(¾ÆÁִ뺴¿ø ¼Ò¾ÆÃ»¼Ò³â°ú), Á¦100ȸ ¾î¸°À̳¯ ¿ÁÁ¶±ÙÁ¤ÈÆÀå
À̺´ÈÆ¡¤½ÉÀç¾Ó ±³¼öÆÀ(±æº´¿ø Á¤Çü¿Ü°ú), ´ëÇѰñÀýÇÐȸ ¿ÃÇØ ¿ì¼ö ±¸¿¬»ó
³²°¡Àº ±³¼ö(°í´ë±¸·Îº´¿ø °¡Á¤ÀÇÇаú), Çѱ¹¿©ÀÚÀÇ»çȸ Á¦4ȸ ÀþÀºÀÇÇÐÀÚ Çмú»ó
±¹¸³Áß¾ÓÀÇ·á¿ø Áß¾ÓÀÀ±ÞÀÇ·á¼¾ÅÍÀå ±è¼ºÁß(Á¶¼±´ëº´¿ø ÀÀ±ÞÀÇÇаú ±³¼ö)
ÃÖÁ¤¿õ ¿µ°æÀÇ·áÀç´Ü ÀüÁÖº´¿ø ÀÌ»çÀå, ¾Æµ¿º¸È£»ç¾÷ ±â±Ý 4000¸¸¿ø
±è¿µÁÖ ±³¼ö(ÀÌ´ë¸ñµ¿º´¿ø »êºÎÀΰú), Á¦13ȸ Çѵ¶¿©ÀÇ»çÇмú´ë»ó
¹ÚÂùÈì ±³¼ö(ÇѸ²´ëÃáõ¼º½Éº´¿ø À̺ñÀÎÈİú), ´ëÇÑÀ̺ñÀÎÈİúÇÐȸ Çмú»ó
Á¶¼öÁø ±³¼ö(ÇѸ²´ëµ¿Åº¼º½Éº´¿ø ½Å°æ°ú), Á¦26ȸ JWÁß¿ÜÇмú´ë»ó
¼­Á¤°Ç ¿¬¼¼¼­³»°ú ¿øÀå ÀåÀλó